Objective Our goals were to estimate the placebo and nocebo responses in restless legs syndrome (RLS). Methods Databases were searched up to October 2015. Randomised, double-blind, placebo-controlled trials of RLS patient were included. 'Placebo response' was defined as the withingroup change from baseline, using any scale measuring RLS severity or disability. 'Nocebo response' was defined as the proportion of patients experiencing adverse events in the placebo arm. Random-effects meta-analysis was used to pool data. Results We included 5046 participants. Pooled placebo response effect size was À1.41 (95%CI:À1.56-À1.25), corresponding to À6.58 points in the International RLS Study Group Scale (IRLS). Pooled nocebo response was 45.36% (95%CI:40.47%-50.29%). The placebo and nocebo responses were greater in trials with longer duration, evaluating pharmacological interventions and idiopathic RLS, and in industry funded and unpublished studies. The placebo response was considerable smaller in objective as compared to subjective outcomes. In addition, the nocebo response increases proportionally with the placebo response, and has the same predictors. Conclusions The magnitude of the placebo response in RLS is above the threshold of minimal clinical important difference, and the frequency of adverse events is also considerable. These results are relevant to inform the design and interpretation of future clinical trials.
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PO105 LEVODOPA-INDUCED DYSKINESIAS IN PARKINSON'S:
IMAGING OF STRIATAL DAT DENSITY OVER TIME Background/Aim The density of the dopamine transporter (DAT) continues to decline in the striatum of Parkinson's disease (PD) patients, while they get at risk for developing levodopa-induced dyskinesias (LIDs). Here, we studied the role of DAT-specific imaging as a prognostic marker of dyskinesias. Methods We retrospectively selected 42 PD patients who had SPECT imaging with 123I-Ioflupane approximately five years ago during the diagnosis of PD. 15 patients of them were rescanned with 123I-Ioflupane SPECT after 6.3±3.0 years. We divided the PD patients according to the presence or absence of dyskinesias. SPECT data were analysed for the putamen by a semi-quantification approach.
Results 10 PD patients had developed LIDs, while 32 were non-dyskinetic. The putaminal mean 123I-Ioflupane uptake in the LIDs (1.7±0.4) group was not statistically different as compared to the non-LIDs group (1.7±0.5;p>010). All 15 PD patients who had a second SPECT scan showed significant reductions in the putaminal 123I-Iofluplane uptake (p<0.001) as compared to their first scan. Within this subgroup, the LIDs (n=8) had significantly lower DAT uptake (1.1±0.3) as compared to the non-LIDs patients (n=7); (1.5±0.5; p<0.05). Conclusion 123I-Ioflupane SPECT imaging in de novo PD, cannot predict the onset of LIDs within five years from diagnosis. As shown in the group that repeated 123I-Ioflupane SPECT imaging, the onset of LIDs may be linked to a faster decline of putaminal DAT availability. Huntington's disease is an invariably fatal neurodegenerative disorder characterised by a triad of abnormal movement, progressive cognitive impairment and psychiatric or behavioural symptoms. This study looks at 53 patients from The Walton Centre EnrollHD database. In manifest patients, the most common presenting symptoms were psychiatric (n=17), followed by motor (n=13), cognitive (n=4) and mixed (n=2). Depression and bipolar disorder were common comorbidities (n=7, n=11). Of all patients, 29 drank over 14 units; two drank over 30 units a week. Two had a past medical history of alcohol abuse. Musculoskeletal comorbidities were more common in patients who abuse, or have abused alcohol (p<0.0001). The prevalence of psychiatric, cognitive and motor symptoms did not vary significantly with alcohol use. In addition, psychiatric symptoms did not occur earlier when drinking excessively (46 compared to 41 years old). Obsessivity, as measured by the Problem Behaviours Assessment, is on average higher in those that abuse alcohol versus those that do not drink (7.0 and 2.9 respectively). A one-tailed ANOVA indicated that this difference was not significant (p>0.05). The relationship between obsessivity and alcohol abuse is unclear in this small study sample, although it suggests a potential relationship between obsession and alcohol abuse.
